Cancer name Neuroblastoma
Cancer Type NB
Immunotherapy type Immune Checkpoint Therapy;Immunostimulant OR Targeting Therapy
Treatment nivolumab
Drugstatus Approved
Drugbank ID DB09035
Checkpoints PD-1
Signature Type Protein
Signature CXCL9
Official Symbol CXCL9
Mode of action PROT_D_UP
Description for ‘mode of action’:the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation),Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental mouse model
Description In contrast, the combination treatment induced significantupregulation of a number of genes, most of whichwere related to interferon pathways23(Fig. 2B, highlighted inred). In particular, CXCL9, CXCL10, and CXCL11, which areinterferon-induced chemokines, were prominently upregulated.
PMID 28123870
Title Regulation of myeloid cells by activated T cells determines the efficacy of PD-2 blockade